ストックスクリーナーアプリを入手
4.51
4.75%
-0.225
アフターアワーズ：
4.50
-0.010
-0.22%
Aquestive Therapeutics Inc (AQST) 最新ニュース
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest Update - MarketBeat
GSA Capital Partners LLP Acquires 115,223 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Is Aquestive Therapeutics (AQST) the Best Multibagger Stock to Buy Heading into 2025? - Insider Monkey
ARMISTICE CAPITAL, LLC Acquires New Stake in Aquestive Therapeutics Inc - GuruFocus.com
Chartwell Investment Partners LLC Buys New Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Aquestive Therapeutics, Inc. Announces Board and Committee Changes - Marketscreener.com
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewswire
Aquestive Therapeutics to Present at Jefferies and Piper Sandler Healthcare Conferences | AQST Stock News - StockTitan
Undercovered Dozen: Asbury Automotive, Globalstar, Northland Power, Aquestive Therapeutics - Seeking Alpha
(AQST) On The My Stocks Page - Stock Traders Daily
HC Wainwright Issues Pessimistic Estimate for AQST Earnings - MarketBeat
Leerink Partnrs Issues Optimistic Forecast for AQST Earnings - MarketBeat
Aquestive Therapeutics announces board changes - Investing.com India
Aquestive Therapeutics announces board changes By Investing.com - Investing.com UK
Aquestive Therapeutics Advances Drug Candidates Amid Challenges - TipRanks
Lake Street lifts Aquestive stock target, keeps buy on NDA submission - Investing.com UK
Aquestive Therapeutics (NASDAQ:AQST) Receives Buy Rating from HC Wainwright - MarketBeat
Aquestive Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Aquestive Therapeutics: Progress in Drug Innovation - TipRanks
Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates - MSN
Aquestive: Rare Opportunity With Dual Platform Strategy (NASDAQ:AQST) - Seeking Alpha
Aquestive Therapeutics (NASDAQ:AQST) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
Aquestive Therapeutics: Q3 Earnings Snapshot - mySA
Aquestive Therapeutics (AQST) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates - MSN
Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Aquestive Therapeutics reports Q3 EPS (13c), consensus (13c) - TipRanks
AQSTAquestive Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Aquestive Therapeutics Optimistic Financial and Strategic Outlook - TipRanks
Aquestive Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Aquestive Therapeutics Inc (AQST) Q3 2024 Earnings Report Preview: What To Expect - Yahoo Finance
Aquestive Therapeutics Inc (AQST) Q3 2024: Everything You Need T - GuruFocus.com
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives $8.83 Consensus Target Price from Brokerages - MarketBeat
Learn to Evaluate (AQST) using the Charts - Stock Traders Daily
Aquestive Therapeutics (NASDAQ:AQST) Price Target Raised to $13.00 - Defense World
Aquestive Therapeutics (AQST) Set to Announce Quarterly Earnings on Monday - MarketBeat
Leerink raises Aquestive Therapeutics stock PT on 'top-line' study results - Investing.com Canada
Aquestive Therapeutics to Present Subsequent Analysis of - GlobeNewswire
Leerink Partners Raises Aquestive Therapeutics (NASDAQ:AQST) Price Target to $13.00 - MarketBeat
Aquestive Therapeutics (NASDAQ:AQST) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Aquestive Therapeutics’ Breakthrough in Allergy Treatment Study - Yahoo Finance
Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American - GlobeNewswire
Institutions profited after Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) market cap rose US$51m last week but individual investors profited the most - Simply Wall St
Aquestive Therapeutics' SWOT analysis: stock poised for growth as Anaphylm nears FDA submission - Investing.com Australia
Aquestive Therapeutics Pushes Retail Sentiment Into ‘Extremely Bullish’ Zone On OAS Drug Trial Success - Barchart
Aquestive Therapeutics' SWOT analysis: stock poised for growth as Anaphylm nears FDA submission By Investing.com - Investing.com South Africa
Aquestive Therapeutics Inc (AQST) Has Recovered 74.67% From Its Low: Is This The Beginning Of A Trend? - Stocks Register
Aquestive Therapeutics Announces Positive Topline Results - GlobeNewswire
Aquestive Therapeutics a new overweight at Piper on oral film products - MSN
Aquestive Therapeutics to Report Third Quarter 2024 - GlobeNewswire
Aquestive Therapeutics updates bylaws, shortens nomination look-back By Investing.com - Investing.com South Africa
1.01%
0.30%
大文字化:
|
ボリューム (24 時間):